<DOC>
	<DOCNO>NCT00653406</DOCNO>
	<brief_summary>The purpose study explore pharmacokinetic profile safety biweekly ( every 2-week ) intramuscular ( IM ) injection ( 6 injection ) risperidone long act injectable 25 , 37.5 , 50 mg/dose schizophrenic patient . The efficacy study medication also assess .</brief_summary>
	<brief_title>A Pharmacokinetic Safety Study Risperidone Long Acting Injectable Schizophrenic Patients</brief_title>
	<detailed_description>This open-label , multicenter , randomize , 3-arm trial compare pharmacokinetic profile safety profile 3 dose group . There 2 period study : 10-week treatment period 8-week follow-up period . Patients receive 6 injection long act injectable risperidone one dose level ( 25 , 37.5 50 mg ) every 2 week accord randomly assign treatment . Blood sample collect throughout 10-week treatment 8-week follow-up period determine change study drug concentration plasma . Safety assess monitor adverse event , subjective symptoms/objective finding , laboratory test , physical examination , electrocardiogram , injection site reaction , Drug-Induced Extrapyramidal Symptoms Scale ( DIEPSS ) . Efficacy study drug assess base Positive Negative Syndrome Scale ( PANSS ) Clinical Global Impression - Severity ( CGI-S ) Clinical Global Impression - Change ( CGI-C ) scale . The patient receive injection long act injectable risperidone ( either 25 , 37.5 , 50 mg ) muscle every 2 week 10 week total 6 injection .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Japanese patient DSMIV diagnosis schizophrenia A Positive Negative Syndrome Scale ( PANSS ) total score 60 ( include ) 120 ( exclude ) In outpatient ( change institutionalization status trial period allow ) . No DSMIV diagnosis schizophrenia No convulsive disorder epilepsy No neuroleptic malignant syndrome physical fatigue associate dehydration , malnutrition No present illness history diabetes risk diabetes hyperglycemia obesity No hemorrhagic diathesis .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Intramuscular injection</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>